RT, either alone or in combined with chemotherapy, significantly alters systemic immunity in HNSCC. Immunophenotyping and peripheral biomarkers show prognostic potential, supporting their integration into personalized treatment strategies. However, standardized, large-scale longitudinal studies are warranted.
Ferreira et al. (Thu,) studied this question.